hotspot -WSS

hotspot

author：focus 2025-08-31 16:36:31 - browse：64364

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Prior authorization reform is both possible and imperative

WSS

A pediatrician calls for Congress to pass the child tax credit deal

High breast density mammograms need follow

Medicare drug price lawsuits could be good politics for Biden

Inaction leaves children at risk from dangerous chemotherapy drug

Dog Aging Project founders on what lies ahead after losing funding

Dog Aging Project founders on what lies ahead after losing funding

hotspot

hotspot

hotspot

The high cost of giving birth even with insurance

Maisha Meds is a PBM, but don't call it that

Drug repurposing or repositioning? The language matters

Immunocompromised patients offer clues on chronic Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA sets aggressive timeline for overhauling inspection procedures

BioMarin wins approval for gene therapy to treat hemophilia A

Prior authorization reform is both possible and imperative

23andMe had bad news about my health. I wish a person had delivered it

Flu vaccine reformulation won't be easy, manufacturers warn

explore

High breast density mammograms need follow

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Medicare bonuses could stop drug shortages under Senate plan

A pediatrician calls for Congress to pass the child tax credit deal

Pumping milk in bathrooms at health conferences is common

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

focus

Wikipedia

entertainment

knowledge